for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ANI Pharmaceuticals Inc

ANIP.OQ

Latest Trade

72.39USD

Change

0.50(+0.70%)

Volume

56,773

Today's Range

71.56

 - 

73.97

52 Week Range

39.83

 - 

86.67

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Ani Announces Positive Clinical Results From Cortrophin Gel Cortisol Response Study

Oct 3 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI ANNOUNCES POSITIVE CLINICAL RESULTS FROM CORTROPHIN® GEL CORTISOL RESPONSE STUDY.ANI PHARMACEUTICALS - RESULTS INDICATE CORTROPHIN GEL (80 UNITS/ML) IS EFFECTIVE FOR ITS INTENDED USE.ANI PHARMACEUTICALS INC - NO ADVERSE SAFETY EVENTS TO BE REPORTED & MINOR EVENTS WERE AS EXPECTED.ANI PHARMACEUTICALS - SUBMISSION FOR CORTROPHIN GEL COMPREHENSIVE SUPPLEMENTAL NDA FILING PLANNED FOR MARCH 2020.

ANI Pharmaceuticals Reports Q2 GAAP Earnings Per Share $0.53

Aug 7 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS REPORTS SECOND QUARTER RESULTS.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.44.Q2 GAAP EARNINGS PER SHARE $0.53.Q2 REVENUE ROSE 15 PERCENT TO $54.4 MILLION.SEES FY 2019 SALES UP 9 TO 12 PERCENT.SEES FY 2019 REVENUE $220 MILLION TO $226 MILLION.ANI HAS UPDATED ITS FULL YEAR GUIDANCE FOR NET REVENUES DUE TO COMPETITIVE LANDSCAPE OF METHYLPHENIDATE ER MARKET.AS OF JUNE 30, 2019 CASH AND CASH EQUIVALENTS $40.5 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE $5.57 TO $6.21.

ANI Pharmaceuticals Expands Generic Pipeline With Acquisition Of Seven Development Stage Drug Products From Coeptis Pharmaceuticals

June 18 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS EXPANDS GENERIC PIPELINE WITH ACQUISITION OF SEVEN DEVELOPMENT STAGE DRUG PRODUCTS FROM COEPTIS PHARMACEUTICALS, INC..ANI PHARMACEUTICALS EXPANDS GENERIC PIPELINE WITH ACQUISITION OF SEVEN DEVELOPMENT STAGE DRUG PRODUCTS FROM COEPTIS PHARMACEUTICALS, INC..ANI PHARMACEUTICALS INC - DEAL FOR FOR $2.3 MILLION DOLLARS.ANI PHARMACEUTICALS INC - DEAL INCLUDES UP TO $12.0 MILLION IN ADDITIONAL DEVELOPMENT AND COMMERCIAL MILESTONES.

Ani Pharmaceuticals Q1 Adjusted Non-Gaap Earnings Per Share $1.30

May 9 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2019 RESULTS AND REAFFIRMS GUIDANCE.Q1 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.30.Q1 GAAP EARNINGS PER SHARE $0.04.Q1 REVENUE $52.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $50.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.05 -- REFINITIV IBES DATA.REAFFIRMED ITS 2019 FINANCIAL GUIDANCE.

ANI Pharmaceuticals Enters Distribution Agreement With A U.S. Based Injectable Manufacturer

April 15 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS EXPANDS INJECTABLE PORTFOLIO WITH DISTRIBUTION AGREEMENT FOR FDA APPROVED INJECTABLE PRODUCT.ANI PHARMACEUTICALS INC - DISTRIBUTION AGREEMENT WITH A U.S. BASED INJECTABLE MANUFACTURER TO COMMERCIALIZE A UNIQUE SPECIALTY INJECTABLE PRODUCT.ANI PHARMACEUTICALS INC - KEY TERMS OF 10-YEAR AGREEMENT INCLUDE CUMULATIVE MILESTONES OF UP TO $2M, PAYABLE BY ANI.ANI PHARMACEUTICALS INC - UPON LAUNCH, ANI WILL RECEIVE A 50% SHARE OF NET PROFITS GENERATED FROM PRODUCT REVENUES.ANI PHARMACEUTICALS INC - SPECIALTY INJECTABLE PRODUCT WILL BE COMMERCIALIZED IN ANI LABEL.

ANI Pharmaceuticals Reports Q4 and FY2018 Results, Provides 2019 Guidance

Feb 27 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $5.07.Q4 GAAP EARNINGS PER SHARE $1.30.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.

ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.32

Feb 27 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.32.Q4 GAAP EARNINGS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.

ANI Pharmaceuticals-On Dec 27, Co, Units Entered Into Amended & Restated 5-Year Senior Secured Credit Amending Credit Facility Dated Dec 29, 2017

Dec 27 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS - ON DEC 27,CO, UNITS ENTERED INTO AMENDED & RESTATED 5-YEAR SENIOR SECURED CREDIT AMENDING CREDIT FACILITY DATED DEC 29, 2017.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ADDS DELAYED DRAW TERM LOAN FACILITY IN AN AMOUNT UP TO $118.0 MILLION.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT INCREASES BORROWING CAPACITY UNDER REVOLVING LINE OF CREDIT BY $25.0 MILLION TO $75.0 MILLION - SEC FILING.ANI PHARMACEUTICALS - AMENDED CREDIT AGREEMENT ALSO EXTENDS MATURITY, INCLUDING OUTSTANDING $72.2 MILLION INITIAL TERM LOAN, TO DEC 27, 2023.ANI PHARMACEUTICALS SAYS TOTAL SIZE OF AMENDED CREDIT AGREEMENT IS $265.2 MILLION FOLLOWING AMENDMENT AND RESTATEMENT - SEC FILING.

Ani Pharmaceuticals To Repurchase $25 Mln Aggregate Principal Amount Of Notes

Dec 7 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS ENTERS INTO SEPARATE PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF ITS CONVERTIBLE NOTES.ANI PHARMACEUTICALS-ENTERED INTO SEPARATE, PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF OUTSTANDING 3.00% CONVERTIBLE SENIOR NOTES DUE 2019.ANI PHARMACEUTICALS INC - AGREED TO REPURCHASE $25.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES FOR A TOTAL OF $26.1 MILLION IN CASH.ANI PHARMACEUTICALS INC - ANI HAS ALSO ENTERED INTO AN AGREEMENT WITH DEALER PARTY TO CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS.ANI PHARMACEUTICALS INC - ALSO ENTERED INTO AGREEMENTS WITH SUCH DEALER COUNTERPARTY TO UNWIND CERTAIN WARRANT TRANSACTIONS.

Ani Pharmaceuticals reports third quarter results

Nov 6 (Reuters) - ANI Pharmaceuticals Inc <ANIP.O>::ANI PHARMACEUTICALS REPORTS THIRD QUARTER AND YEAR-TO-DATE 2018 RESULTS AND REAFFIRMS GUIDANCE.Q3 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.29.Q3 GAAP EARNINGS PER SHARE $0.42.Q3 REVENUE $50.7 MILLION VERSUS I/B/E/S VIEW $51 MILLION.Q3 EARNINGS PER SHARE VIEW $1.17 -- THOMSON REUTERS I/B/E/S.SAYS REAFFIRMED ITS 2018 FINANCIAL GUIDANCE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up